Opinion|Videos|November 19, 2026

ASCENT-04: Sacituzumab Govitecan Plus Pembrolizumab in First-Line PD-L1–Positive Metastatic TNBC

In this segment, Dr. Gregory Vidal reviews the phase 3 ASCENT-04 trial evaluating sacituzumab govitecan (SG) plus pembrolizumab versus chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive metastatic triple-negative breast cancer (TNBC).

In this segment, Dr. Gregory Vidal reviews the phase 3 ASCENT-04 trial evaluating sacituzumab govitecan (SG) plus pembrolizumab versus chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive metastatic triple-negative breast cancer (TNBC). He outlines the eligibility criteria, treatment regimens, and efficacy findings. Median progression-free survival was 11.2 months with SG plus pembrolizumab versus 7.8 months with chemotherapy plus pembrolizumab, with a hazard ratio of 0.65. Interim overall survival remained immature, with no demonstrated significant difference at the time of analysis. Objective response rates, complete response rates, and duration of response are also reviewed. The panel discusses safety and tolerability, including treatment discontinuations, dose modifications, and adverse events associated with both regimens. Experts consider how crossover to subsequent SG may affect interpretation of overall survival and compare ASCENT-04 with the previously discussed trials, while emphasizing the limitations of cross-trial comparisons. The discussion also explores the relevance of ASCENT-04 in the evolving treatment landscape following KEYNOTE-522, the potential influence of toxicity and dose reductions on treatment decisions, and the importance of supportive care measures such as prophylaxis for neutropenia and diarrhea. The segment concludes with a focus on individualizing treatment for older adults and balancing efficacy, treatment burden, tolerability, and quality of life when selecting therapy for metastatic TNBC.


Related to this article